(Q42687717)

4 November 2017

Influence of patient co-payments on atypical antipsychotic choice in Poland: implications once generic atypicals are available (English)

1 reference

4 November 2017

1 reference

1 reference

Magda Wladysiuk

1

1 reference

4 November 2017

Brian Godman

3

1 reference

4 November 2017

Katarzyna Szabert

4

1 reference

4 November 2017

Corrado Barbui

5

1 reference

4 November 2017

Alan Haycox

6

1 reference

4 November 2017

1 March 2011

1 reference

Applied Health Economics and Health Policy

4 November 2017

1 reference

4 November 2017

9

1 reference

4 November 2017

2

1 reference

4 November 2017

101-110

1 reference

https://scigraph.springernature.com/pub.10.2165/11318840-000000000-00000

4 November 2017

0 references

cites work

Economic issues in access to medications: schizophrenia treatment in England.

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Impact of regulatory changes on first- and second-generation antipsychotic drug consumption and expenditure in Italy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Prevalence, incidence and persistence of antipsychotic drug prescribing in the Italian general population: retrospective database analysis, 1999-2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Use of antipsychotic medications in Australia between July 1995 and December 2001.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Treatment persistence: a comparison among patients with schizophrenia who were initiated on atypical antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Head-to-head comparison of the costs of atypical antipsychotics: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Modern antipsychotic drugs: a critical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

The spurious advance of antipsychotic drug therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Effectiveness and cost of risperidone and olanzapine for schizophrenia: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Cost comparisons of olanzapine and risperidone in treating schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Outpatient antipsychotic treatment and inpatient costs of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Affordability of medicines and patients' cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Generic olanzapine: health authority opportunity or nightmare?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Generic and therapeutic substitutions in the UK: are they a good thing?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Prescription drug cost sharing: associations with medication and medical utilization and spending and health.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Use of Generics-A Critical Cost Containment Measure for All Healthcare Professionals in Europe?

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Insight into recent reforms and initiatives in Austria: implications for key stakeholders

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Initiatives to enhance renin-angiotensin prescribing efficiency in Austria: impact and implications for other countries

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Ongoing pharmaceutical reforms in France: implications for key stakeholder groups

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

Prescription drug co-payments and cost-related medication underuse

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F11318840-000000000-00000

10.2165/11318840-000000000-00000

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

4 November 2017

0 references

1 reference